^
    Back
    Association details:
    Biomarker:DDR signature score
    Cancer:Triple Negative Breast Cancer
    Drug:carboplatin (Tubulin polymerization promoter)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

    Published date:
    08/14/2023
    Excerpt:
    DDR markers separated carboplatin responders from nonresponders (P values = 0.017; 0.046). High immune infiltration was associated with docetaxel ORR (interaction P values < 0.05)….High immune features predict docetaxel response, and high DDR signature scores predict carboplatin response in treatment-naïve mTNBC. Integrating multimodal DDR and immune-related markers identifies subgroups with differential treatment sensitivity.
    DOI:
    https://doi.org/10.1158/1078-0432.CCR-23-0370
    Trial ID:
    NCT00532727